Articles tagged "Immunosuppression"

2017 American Transplant Congress
Immunosuppressive Therapy and Acute Rejection in Combined Heart and Kidney Transplantation.
M. Gallo, J. Trivedi, D. Abramov, R. Vijayakrishnan, M. Slaughter.
University of Louisville, Louisville
Background. This study evaluated the management of immunosuppressive therapy and the incidence of acute heart rejection within 1 year from concomitant heart-kidney transplantation (cHTKx) compared…
2017 American Transplant Congress
In Vitro Optimisation of the Immunotherapeutic Effects of Umbilical Cord Derived MSC.
S. de Witte,¹ A. Merino,¹ M. Franquesa,¹ T. Strini,¹ J. van Zoggel,¹ S. Korevaar,¹ F. Luk,¹ M. Gargesha,⁴ D. Roy,⁴ S. Elliman,² P. Newsome,³ C. Baan,¹ M. Hoogduijn.¹
¹Department of Internal Medicine, ErasmusMC, Rotterdam, Netherlands; ²Orbsen Therapeutics Ltd., Galway, Ireland; ³Department of NIHR Liver Biomedical Research Unit and Centre for Liver Research, University of Birmingham, Birmingham, United Kingdom; ⁴BioInVision Inc., Mayfield Village
Mesenchymal stromal cells (MSC) possess immunomodulatory properties and are low immunogenic, which are both important for their development into an effective cellular immunotherapy after organ…
2017 American Transplant Congress
Population Pharmacokinetic Profiling of Tacrolimus in Renal Transplant Recipients (RTRs) Taking Diltiazem.
P. Trevillian,^1,2,3 M. Heer,^1,2 S. Ainsworth,¹ A. Hibberd.^1,2,3
¹Newcastle Transplant Unit, John Hunter Hospital, Newcastle, NSW, Australia; ²University of Newcastle, Newcastle, NSW, Australia; ³Hunter Transplant Research Foundation, Hunter Medical Research Institute, Newcastle, NSW, Australia
Background: Over the past 6 years we have prospectively used pharmacokinetic (PK) profiling of Tacrolimus (TAC) in “stable” RTR's to individualise future dosing. This study…
2017 American Transplant Congress
Evaluation of the Conversion from Brand Name to Generic Immunosuppression in Hospitalized Organ Transplant Recipients.
L. DeZotell,¹ K. Blunck,¹ J. Guy,¹ M. Woods,¹ M. Reffett,² J. Terrell,² A. Palermo,² K. Gosch,³ L. Cummings.⁴
¹Department of Pharmacy, Saint Luke's Hospital, Kansas City, MO; ²Transplant Quality Department, Saint Luke's Hospital, Kansas City, MO; ³Cardiovascular Outcomes Research, Saint Luke's Hospital, Kansas City, MO; ⁴Abdominal Transplant and HPB Surgery, Saint Luke's Transplant Specialists, Kansas City, MO
Purpose: Safe and effective immunosuppressant medications are critical to accomplish good graft and patient survival rates. The availability of “AB-rated” generic immunosuppression affords the opportunity…
2017 American Transplant Congress
Evaluation of Renal Function After a Transition to Everolimus or Mycophenolate Mofetil in Liver Transplant Recipients.
C. Perez,¹ J. Fleming,¹ M. Sell,¹ B. O'brien,¹ A. Rogers,¹ I. Lee,¹ C. Mardis,¹ A. Mardis,¹ N. Patel,¹ H. Meadows,¹ N. Pilch,² K. Chavin,² D. Dubay,² R. Vinayak,² D. Taber.²
¹Pharmacy, Medical University of South Carolina, Chareleston, SC; ²Surgery, Medical University of South Carolina, Charleston, SC
Purpose: The aim of this study was to assess if there is a difference in renal function over time when transitioning to everolimus vs. mycophenolate.Methods:…
2017 American Transplant Congress
A Search for a Biomarker Which Predicts Belatacept-Resistant Rejection.
G. de Graav,¹ C. Baan,¹ M. Clahsen-van Groningen,² R. Kraaijeveld,¹ M. Dieterich,¹ W. Verschoor,¹ D. Roelen,³ M. Cadogan,¹ J. van de Wetering,¹ J. van Rosmalen,⁴ W. Weimar,¹ D. Hesselink.¹
¹Internal Medicine, Erasmus University Medical Center, Rotterdam, South Holland, Netherlands; ²Pathology, Erasmus University Medical Center, Rotterdam, South Holland, Netherlands; ³Immunohematology and Blood Transfusion, Erasmus University Medical Center, Rotterdam, South Holland, Netherlands; ⁴Biostatistics, Erasmus University Medical Center, Rotterdam, South Holland, Netherlands
Belatacept, an inhibitor of the CD28-CD80/86 costimulatory pathway, has been associated with a higher acute rejection risk than ciclosporin. We sought to identify a biomarker…
2017 American Transplant Congress
The Associations Between Body Mass Index and Kidney Transplant Outcomes Are Mediated by Weight-Adjusted Immunosuppression Dosing.
K. Flabouris,^1,2 S. Chadban,^1,3,4 M. Ladhani,^1,3,5 M. Cervelli,⁶ P. Clayton.^1,2,6
¹Australia and New Zealand Dialysis and Transplant (ANZDATA) Registry, Adelaide, Australia; ²School of Medicine, University of Adelaide, Adelaide, Australia; ³Sydney Medical School, University of Sydney, Sydney, Australia; ⁴Department of Renal Medicine, Royal Prince Alfred Hospital, Sydney, Australia; ⁵Department of Renal Medicine, Lyell McEwin Hospital, Adelaide, Australia; ⁶Central Northern Adelaide Renal and Transplantation Service, Royal Adelaide Hospital, Adelaide, Australia
Purpose: High body mass index (BMI) is associated with acute rejection after kidney transplantation. We hypothesised that weight-adjusted immunosuppression dosing is a contributing factor. We…
2017 American Transplant Congress
Rituximab Desensitization (DES) and Alemtuzumab Induction Significantly Reduced EBV Viremia and Post-Transplant Lymphoproliferative Disorder (PTLD) in HLA-Sensitized (HS) Kidney Transplant Patients.
B.-H. Shin,¹ S. Ge,¹ J. Mirocha,² D. Thomas,¹ E. Rodriguez,¹ C. Chao,¹ O. Galera,¹ A. Vo,¹ J. Choi,¹ A. Peng,¹ J. Kahwaji,¹ S. Jordan,¹ M. Toyoda.¹
¹Transplant Immunology Laboratory and Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA; ²Biostatistics Core, Cedars-Sinai Medical Center/UCLA School of Medicine, Los Angeles, CA
Background: PTLD is a serious complication in KTx pts and is usually associated with EBV infection. Recent studies showed that rituximab treatment prior to Tx…
2017 American Transplant Congress
Tacrolimus and Mycophenolic Acid Have a Limited Inhibitory Effect on Monocyte Signaling Pathway Phosphorylation, Function and Differentiation.
N. Kannegieter,¹ D. Hesselink,¹ M. Dieterich,¹ R. Kraaijeveld,¹ A. Rowshani,¹ P. Leenen,² C. Baan.¹
¹Internal Medicine, Erasmus MC, Rotterdam, Netherlands; ²Immunology, Erasmus MC, Rotterdam, Netherlands
Introduction Monocytes and macrophages play key roles in cellular and humoral rejection after solid organ transplantation, but little is known about the effects of the…
2017 American Transplant Congress
The Inhibitory Effect of Plasma on T Cell Activation: Possible Role of Plasma Exchange in Anti Rejection Therapy.
A. Assounga,^1,2 S. Omarjee.¹
¹Dept Nephrology, University of KwaZulu-Natal, Durban, South Africa; ²Inkosi Albert Luthuli Central Hospital, Durban, South Africa
Reduction of lymphocyte proliferation by human plasma has been previously reported. Reduced activation of lymphocytes of patients on immunosuppressive drugs is well documented.Aim: To compare…